Is Regeneron Pharmaceuticals (REGN) overvalued or fairly valued?

MarketChacha shows Regeneron Pharmaceuticals's valuation in context — a trailing P/E of about 18.2, a forward P/E of about 13.7, a price-to-book of about 2.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Regeneron Pharmaceuticals's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.09×) from reported figures — education, not a rating.

What is Regeneron Pharmaceuticals's revenue?

Regeneron Pharmaceuticals reported revenue of $14.3B for FY2025, with net profit of $4.5B, per official filings.

What is the share price of Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals last traded at $827.72 (-1.9% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Regeneron Pharmaceuticals

REGN · NASDAQ · Healthcare · United States

Snapshot

TickerREGN

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees15,410

HeadquartersTarrytown, United States

Websitewww.regeneron.com

Filings tracked15

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Who owns it

Insiders2.1%
Institutions93.6%
Public & other4.3%

1,921 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.01%
Vanguard Capital Management LLC6.56%
Dodge & Cox Inc.4.82%
State Street Corporation4.78%
Invesco Ltd.3.90%
JPMORGAN CHASE & CO3.73%
Vanguard Portfolio Management LLC3.14%
Franklin Resources, Inc.2.74%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.09×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend30.1% → 31.4%

Margin has expanded by about 1.3 points — the business is getting more profitable.

Growth qualityrev 5% · PAT 7%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $4.6B · EPS 15.61

Est. earnings growth +36.4%

Next fiscal year

Rev $18.4B · EPS 50.38

Est. earnings growth +13.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$14.3B

Net margin

31.4%

ROE

14.4%

Revenue CAGR (2y)

+4.6%

Profit CAGR (2y)

+6.7%

EPS (FY2025)

41.48

Net profit (FY2025)

$4.5B

Ask MarketChacha about REGN

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$14.3B	$4.5B	41.48	31.4%	14.4%
FY2024	$14.2B	$4.4B	38.34	31.1%	15.0%
FY2023	$13.1B	$4.0B	34.77	30.1%	15.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$4.3B	$1.3B	12.23	30.2%
2026Q1	$3.6B	$727.2M	6.75	20.2%
2025Q3	$3.8B	$1.5B	13.62	38.9%
2025Q2	$3.7B	$1.4B	12.81	37.9%
2025Q1	$3.0B	$808.7M	7.27	26.7%
2024Q3	$3.7B	$1.3B	11.54	36.0%
2024Q2	$3.5B	$1.4B	12.41	40.4%
2024Q1	$3.1B	$722.0M	6.27	23.0%
2023Q3	$3.4B	$1.0B	8.89	30.0%
2023Q2	$3.2B	$968.4M	8.50	30.7%
2023Q1	$3.2B	$817.8M	7.17	25.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC7/30/2026material
10-Q filing
SEC7/30/2026
8-K — Results of operations
SEC7/6/2026material
8-K — Shareholder vote results
SEC6/17/2026material
8-K — Results of operations, Exhibits
SEC4/29/2026material
10-Q filing
SEC4/29/2026
8-K — Results of operations
SEC4/8/2026material
10-K filing
SEC2/4/2026
8-K — Results of operations, Exhibits
SEC1/30/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Results of operations, Exhibits
SEC10/28/2025material
10-Q filing
SEC10/28/2025
8-K — Results of operations
SEC10/6/2025material
8-K — Results of operations, Exhibits
SEC8/1/2025material
10-Q filing
SEC8/1/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.